Levels of Immune Marker TREM2 Rise Years Before Alzheimer’s Disease Becomes Apparent

Researchers reported that TREM2 levels rise early on in the progression of Alzheimer’s disease, and that the biomarker might be useful in clinical research to evaluate the benefits of new AD therapies on neuroinflammation, or may one day be a therapeutic target itself.

Levels of an immune cell receptor called TREM2 were found to increase early on in the progression of Alzheimer’s disease (AD),

Dementia risk in renal dysfunction

ABSTRACT

Objective: Renal dysfunction has been linked with increased risk for cognitive impairment and dementia, but studies are conflicting. For that reason, the aim of the present systematic review and meta-analysis is to summarize the best available evidence on the prospective association between potential markers of renal dysfunction and development of cognitive impairment or dementia.

Dementia with Lewy bodies and Parkinson disease with dementia

The article by Thomas et al. validated 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of autopsy-proven dementia with Lewy bodies (DLB). [1] The authors depicted 3 patients with DLB who met pathologic criteria for LBD but had normal 123I-FP-CIT imaging. [1] Although further description concerning severity of parkinsonism remains unclear, these patients may not have severe parkinsonism.

Doctor Tuchman’s Interview on Dementia with Lewy Bodies

Dr. Michael Tuchman was recently interviewed by the Palm Beach Post in regards to dementia with Lewy Bodies, or “DLB,” the effects it has and how it affected a Palm Beach Gardens couple. DLB is caused by the buildup of protein clusters in the brain and symptoms include rapid mood swings, insomnia and nightmares, hallucinations and memory loss.

Calcium Supplements May Be Associated with an Increased Risk for Dementia, Study Finds

Researchers reported an associated risk between calcium supplementation and the development of dementia in women with cerebrovascular disease. But the study authors and independent experts said the five-year population-based study sample was too small and the findings are premature and need to be replicated in a larger study.

Calcium supplements may raise the risk of dementia in elderly women with cerebrovascular disease,

Aerobic Exercise Found to Improve Cognition in Mild Vascular Cognitive Impairment

Investigators reported that, in a randomized controlled trial, patients with vascular cognitive impairment showed improvement on cognitive tests after participating in a six-month exercise program. Independent experts said the findings were promising, but preliminary.

Progressive aerobic-exercise training for six months appeared to improve cognition in adults with mild subcortical ischemic vascular cognitive impairment,

Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases

Objective: To determine whether cognitive impairment in Parkinson disease (PD) and Alzheimer disease (AD) derives from the same network pathology.

Methods: We analyzed 18F-fluorodeoxyglucose PET scans from 40 patients with AD and 40 age-matched healthy controls from the Alzheimer’s Disease Neuroimaging Initiative and scanned an additional 10 patients with AD and 10 healthy controls at The Feinstein Institute for Medical Research to derive an AD-related metabolic pattern (ADRP) analogous to our previously established PD cognition-related pattern (PDCP) and PD motor-related pattern (PDRP).

Thalamo-cortical network activity during spontaneous migraine attacks

Objective: We used MRI to search for changes in thalamo-cortical networks and thalamic microstructure during spontaneous migraine attacks by studying at the same time structure with diffusion tensor imaging and resting state function in interconnected brain networks with independent component analysis.

Methods: Thirteen patients with untreated migraine without aura (MI) underwent 3T MRI scans during an attack and were compared to a group of 19 healthy controls (HC).

Potential Treatment for Early Onset Alzheimer’s…Currently Enrolling

Description

A global clinical research study assessing the effectiveness and safety of an investigational medication designed to slow the progression of early Alzheimer’s disease.

The ENGAGE study is split into two phases: a placebo-controlled phase, and an optional long-term extension phase.

In the placebo-controlled phase, eligible participants will have a 2-in-3 chance of receiving the investigational medication and a 1-in-3 chance of receiving the placebo.

Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease…Currently Enrolling

A Randomized, Placebo controlled, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease. (Prodromal AD)

This is an 18 month study in which subjects that screen and qualify will go onto the program taking the investigation medication by mouth once daily.